Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.
Leukemia
; 27(10): 2032-9, 2013 Oct.
Article
in En
| MEDLINE
| ID: mdl-23860450
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neoplasm, Residual
/
Janus Kinase 2
/
Real-Time Polymerase Chain Reaction
/
Mutation
/
Myeloproliferative Disorders
/
Neoplasm Recurrence, Local
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Health_economic_evaluation
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
En
Journal:
Leukemia
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
Year:
2013
Document type:
Article
Affiliation country:
United kingdom
Country of publication:
United kingdom